ArticleJournal of the National Cancer Center2024
Cancer survival statistics in China 2019-2021: a multicenter, population-based study.
Article in Journal of the National Cancer Center, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
138 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Incidence and influencing factors of chemotherapy-induced peripheral neuropathy in cancer patients: a systematic review and meta-analysis.Frontiers in neurologyPooled it
- Effects of self-acupressure on the fatigue-sleep disturbance-depression symptom cluster in breast cancer survivors: a phase III randomised controlled trial.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Trial
- Effect of endoscopic screening for non-cardia gastric cancer: a 12-year report of a population-based randomized trial.BMC medicine · 2026Trial
- RhTSH in aiding dynamic assessment in patients with differentiated thyroid Cancer.European journal of nuclear medicine and molecular imaging · 2025Trial
- Neoadjuvant serplulimab and SOX chemotherapy for locally advanced gastric cancer: pathological responses and systemic immune signatures from a phase II trial.Frontiers in immunology · 2025Trial
- Integrated bioinformatics and feature selection-based discovery of ADP-ribosylation-associated biomarkers in non-small cell lung cancer.Oncology letters · 2026Article
- Metabolic Signatures for Liver Cancer Diagnosis and Mechanistic Insights: A Large-Scale, Multicenter Study.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Interventional Management of Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombosis: Are There Differences Between East and West?Current oncology reports · 2026Review
- Symptom clusters and quality of life among patients with thyroid cancer during early survivorship: a national multicenter cross-sectional study.The oncologist · 2026Article
- Cancer burden and control in China: landscape, trends and challenges.Nature reviews. Clinical oncology · 2026Review
- CSNK2B Expression Aligns with a GDF15-Associated Immune Molecular State in Hepatocellular Carcinoma.Biomedicines · 2026Article
- Association of Life's Essential 8 Score With Incident Pancreatic Cancer: A Prospective Cohort Study in Shanghai, China.Cancer science · 2026Article
- SNX8 regulates BMPR2-mediated SMAD5 proteostasis to drive epithelial-mesenchymal transition in hepatocellular carcinoma.Journal of translational medicine · 2026Article
- [Current status of prostate cancer screening research].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026Review
- Potentially Functional Variants in FCER1A and PLCG2, Two B Cell-Related Immune Genes Predict the Survival of Chinese Gastric Cancer Patients.Molecular carcinogenesis · 2026Article
- Schisandrin B exhibits anti‑proliferative effects by inducing ferroptosis in pancreatic cancer.Oncology reports · 2026Article
- Cost-Effectiveness of olaparib plus bevacizumab versus bevacizumab monotherapy as first-line maintenance for patients with advanced ovarian cancer: a analysis from a Chinese healthcare perspective.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2026Article
- Nanoparticle Boron Carrier for Boron Neutron Capture Therapy: Research Progress and Perspectives in China.Nanomaterials (Basel, Switzerland) · 2026Review
- Artificial intelligence-based multimodal multitask analysis of thyroid ultrasound image features predicts thyroid cancer: a multicenter study.JNCI cancer spectrum · 2026Article
- Safety and efficacy of JWATM204, a novel Glypican-3 (GPC3)-targeted CAR T cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study.Cancer pathogenesis and therapy · 2026Article
78 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A milestone goal of the Healthy China Program (2019-2030) is to achieve 5-year cancer survival at 43.3% for all cancers combined by 2022. To assess the progress towards this target, we analyzed the updated survival for all cancers combined and 25 specific cancer types in China from 2019 to 2021. Methods: We conducted standardized data collection and quality control for cancer registries across 32 provincial-level regions in China, and included 6,410,940 newly diagnosed cancer patients from 281 cancer registries during 2008-2019, with follow-up data on vital status available until December 2021. We estimated the age-standardized 5-year relative survival overall and by site, age group, and period of diagnosis using the International Cancer Survival Standard Weights, and quantified the survival changes to assess the progress in cancer control. Results: In 2019-2021, the age-standardized 5-year relative survival for all cancers combined was 43.7% (95% confidence interval [CI], 43.6-43.7). The 5-year relative survival varied by cancer type, ranging from 8.5% (95% CI, 8.2-8.7) for pancreatic cancer to 92.9% (95% CI, 92.4-93.3) for thyroid cancer. Eight cancers had 5-year survival of over 60%, including cancers of the thyroid, breast, testis, bladder, prostate, kidney, uterus, and cervix. The 5-year relative survival was generally lower in males than in females. From 2008 to 2021, we observed significant survival improvements for cancers of the lung, prostate, bone, uterus, breast, cervix, nasopharynx, larynx, and bladder. The most significant improvement was in lung cancer. Conclusions: Progress in cancer control was evident in China. This highlights the importance of a comprehensive approach to control and prevent cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.